Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
BBB

Ratings ESG MSCI

Ratings Integra LifeSciences Holdings Corporation: Strengths and Weaknesses

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Highlights: Integra LifeSciences Holdings Corporation
  • The company appears to be poorly valued given its net asset value.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses: Integra LifeSciences Holdings Corporation
  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • One of the major weak points of the company is its financial situation.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • The company's earnings releases usually do not meet expectations.

Rating Financials

Integra LifeSciences Holdings Corporation SectorUnited States

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Integra LifeSciences Holdings Corporation SectorUnited States

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

-

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Integra LifeSciences Holdings Corporation SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Integra LifeSciences Holdings Corporation SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Integra LifeSciences Holdings Corporation SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
1.27B
BBB
171B
BBB
110B
BBB
106B
AA
75.99B
AA
57.3B
AA
48.76B
A
50.19B
AAA
41.14B
AAA
32.56B
BBB
Average 69.42B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. IART Stock
  4. Ratings Integra LifeSciences Holdings Corporation